CJC-1295

Overview

CJC-1295 is a synthetic GHRH analog that occupies a distinctive position in the growth hormone optimization landscape because it exists in two very different clinical forms: a short-acting version with a half-life of about 30 minutes, and a long-acting version with an attached linker that binds albumin and extends its half-life to 6 to 8 days. These two forms produce different patterns of growth hormone release — pulsatile versus sustained — and the clinical choice between them is one of the most-discussed patient questions in peptide therapy.

Tennessee clinics typically use the short-acting form in combination with ipamorelin, which produces what is arguably the most-prescribed peptide stack in growth hormone optimization. The long-acting form is used in protocols that prioritize dosing convenience or sustained GH elevation, accepting that the sustained “GH bleed” departs somewhat from the body’s natural pulsatile pattern.

CJC-1295 is not FDA-approved for any indication. It was developed in the 2000s with early-phase human trials demonstrating substantial GH and IGF-1 elevation, but the formal development program was discontinued and FDA approval was not pursued. As of 2026, CJC-1295 is available through 503A compounding pharmacies under valid prescriptions and is one of the more commonly prescribed peptides in Tennessee functional medicine and peptide-focused practice.

How CJC-1295 Works

CJC-1295 is a synthetic 30-amino-acid GHRH analog. Structurally, it begins with the same GHRH 1-29 sequence as sermorelin and adds specific amino acid substitutions designed to resist enzymatic degradation. The two clinical forms differ in one critical structural feature.

The short-acting form (no-DAC). This is the basic CJC-1295 GHRH analog without an albumin-binding modification. Its half-life is short — approximately 30 minutes — meaning it produces a brief, pulse-like GH release that closely mimics endogenous GHRH activity. After injection, GH levels rise briefly and then return to baseline, preserving the natural pulsatile rhythm and the IGF-1-mediated feedback loop.

The long-acting form (with DAC). The “DAC” stands for Drug Affinity Complex — a maleimido propionic acid linker covalently attached to the peptide. This linker binds to serum albumin in circulation, dramatically extending the peptide’s half-life from 30 minutes to roughly 6 to 8 days. After injection, GH levels rise and remain elevated for a week or more — a pattern sometimes informally called a “GH bleed.” This is mechanistically distinct from the natural pulsatile rhythm: it is sustained, non-pulsatile elevation that the body would not normally produce on its own.

Both forms activate the same GHRH receptor and trigger the same downstream GH release. The difference is entirely in pharmacokinetics — how long the receptor activation lasts. This pharmacokinetic difference produces meaningfully different clinical experiences and is the basis for the choice between the two forms.

Downstream of GH release, the principal mediator is IGF-1, produced primarily by the liver in response to GH stimulation. IGF-1 drives most of the tissue-level metabolic and anabolic effects associated with growth hormone, including effects on body composition, recovery, and tissue repair.

CJC-1295 No-DAC vs With DAC

This is the most-asked patient question about CJC-1295, and it deserves a dedicated, honest explanation.

No-DAC: preserves pulsatility. The short-acting form produces a discrete pulse of GH release that mimics the body’s natural pattern. This is consistent with the pulsatile architecture of physiologic GH secretion, where the pituitary releases GH in bursts (most prominently during slow-wave sleep) with low baseline levels in between. Many clinicians argue that preserving this pulsatile pattern is more physiologic and may carry a more favorable long-term safety profile than sustained elevation, though the long-term comparative data is limited.

The no-DAC form requires more frequent dosing — typically once daily, sometimes 2 to 3 times daily — because the short half-life means each injection produces only a brief GH release. In practice, this is rarely a problem because no-DAC CJC-1295 is almost always combined with ipamorelin in a single combined-stack injection, and the patient is already committing to daily peptide administration.

With DAC: sustained elevation. The long-acting form produces sustained, non-pulsatile GH elevation lasting roughly a week per injection. This is dosing-convenient — once or twice weekly versus daily — and produces higher and more persistent IGF-1 levels. Some clinicians and patients prefer this profile for body composition and recovery applications where sustained anabolic signaling is the goal.

The trade-off is that the sustained “GH bleed” is not physiologic. The body’s pituitary does not normally release GH in this pattern. Whether chronic sustained elevation produces effects that pulsatile elevation does not — for better or for worse — is not fully characterized. Some clinicians prefer to preserve pulsatility on principle; others prioritize convenience and sustained exposure.

Practical guidance. In Tennessee clinical practice, the no-DAC form is the more common choice when paired with ipamorelin in daily protocols. The with-DAC form is used when dosing convenience is paramount or when the clinical goal explicitly favors sustained GH elevation. Patients should expect their Tennessee provider to articulate a specific rationale for the form they prescribe rather than treating the choice as interchangeable.

Clinical Evidence

CJC-1295’s clinical evidence base is principally from early-phase human pharmacology studies conducted by the original developer in the 2000s. These studies demonstrated that the with-DAC form, given as a single subcutaneous injection, produced significant and sustained GH and IGF-1 elevation lasting up to 7 to 10 days in healthy adults [1]. The pharmacokinetics — half-life, exposure, GH response — were well-characterized.

The development program for clinical indication was discontinued, and no large phase 3 trials were conducted. FDA approval was not pursued. The reasons for discontinuation are typically described as commercial rather than safety- or efficacy-related, though the absence of completed phase 3 data is meaningful.

For the off-label applications that drive most current clinical demand — adult growth hormone optimization, anti-aging, recovery, body composition support — there are no large randomized placebo-controlled trials. The clinical evidence base is the pharmacology (the peptide reliably elevates GH and IGF-1), the related literature on sermorelin and other GHRH analogs, and accumulated clinician experience.

For Tennessee patients, the appropriate framing is that CJC-1295 has solid mechanistic and pharmacologic credentials but lacks the kind of trial-grade efficacy evidence that supports FDA approval. The peptide does what it is supposed to do biochemically. Whether the resulting GH/IGF-1 elevation produces meaningful clinical benefit for the off-label indications is supported by mechanistic logic and provider experience rather than randomized trial data.

Common Clinical Applications

In Tennessee clinical practice, CJC-1295 (in either form, most commonly with ipamorelin) is prescribed for several overlapping use cases.

Adult growth hormone optimization. Patients with age-related decline in GH secretion, low-normal IGF-1, and clinical symptoms (fatigue, suboptimal recovery, body composition changes, sleep disturbances) arrive at CJC-1295/ipamorelin protocols as a common first-line peptide intervention.

Recovery and athletic performance. Active adults describe improved recovery, better sleep quality, and incremental body composition support over a 3 to 6 month course. The mechanistic basis is GH/IGF-1 support for tissue repair and glycogen restoration.

Sleep quality. GH release is closely tied to slow-wave sleep architecture, and the no-DAC form (dosed pre-bed with ipamorelin) is reported by many patients to improve sleep depth and morning recovery.

Body composition. Some patients report modest improvements in lean mass and reductions in adiposity over a course, often combined with resistance training and dietary changes. Magnitude of effect varies considerably.

Anti-aging and longevity protocols. CJC-1295 is a common component of broader hormone optimization and longevity programs, layered with sleep, training, and dietary interventions rather than used as a standalone anti-aging therapy.

CJC-1295 + Ipamorelin: The Classic Stack

The CJC-1295 (no-DAC) plus ipamorelin combination is the most widely-prescribed peptide stack in growth hormone optimization, and understanding the rationale for the combination is essential to understanding how CJC-1295 is used in clinical practice.

GH release from the pituitary is regulated by two opposing inputs: GHRH (stimulates GH release) and somatostatin (suppresses it). The pituitary has GHRH receptors and also ghrelin/growth hormone secretagogue receptors, and activation of either receptor triggers GH release through partially overlapping but partially distinct intracellular signaling pathways.

• CJC-1295 is a GHRH analog and binds the GHRH receptor.
• Ipamorelin is a GHRP and binds the ghrelin/growth hormone secretagogue receptor.

When the two pathways are activated simultaneously, the resulting GH release is greater than the sum of either peptide alone — a synergistic effect that has been demonstrated in pharmacology studies of GHRH/GHRP combinations across multiple peptide pairs.

The practical implication is that combining a GHRH analog and a GHRP allows for lower individual doses of each peptide while achieving greater total GH release. Most Tennessee clinics dispense CJC-1295 (no-DAC) and ipamorelin as a combined reconstitution that can be drawn into a single injection, simplifying patient adherence.

The no-DAC form of CJC-1295 is most commonly used in this stack because the short, pulsatile activation of the GHRH receptor aligns naturally with the also-pulsatile ipamorelin signal from the ghrelin receptor. The with-DAC form is used less frequently in combination protocols because its sustained activation pattern is less conceptually compatible with the pulsatile philosophy of the combined stack.

What to Expect on a CJC-1295 Course

Patients beginning a CJC-1295 protocol — most commonly with ipamorelin — should expect a structured experience with reassessment points.

Baseline assessment. Most Tennessee clinics begin with a focused history (cancer history, diabetes status, pregnancy status, current medications including glucocorticoids) and baseline labs. Standard baseline labs typically include IGF-1, HbA1c or fasting glucose, lipid panel, basic metabolic panel, and sometimes thyroid function.

Choice of form. The no-DAC versus with-DAC decision is typically made at the first visit based on the patient’s goals, dosing preferences, and the clinician’s protocol philosophy. Patients who value preserving the natural pulsatile rhythm and who are willing to commit to daily injection typically receive the no-DAC form. Patients who prioritize convenience or sustained elevation typically receive the with-DAC form.

Initiation. Injection technique is reviewed at the first visit. The no-DAC form is typically dispensed combined with ipamorelin in a single reconstituted vial for once-daily pre-bed injection. The with-DAC form is dispensed as a separate vial for weekly or twice-weekly injection.

Weeks 1 to 2. Most patients describe sleep changes as the first noticeable effect — deeper sleep, vivid dreams, easier morning waking. Some patients describe mild headache or flushing in the first injections that resolves with continued use. Water retention (more prominent on the with-DAC form) may be noticeable in this window.

Weeks 3 to 8. Recovery effects (faster post-exercise recovery, less persistent soreness), body composition changes, and subjective energy improvements accumulate gradually. The pattern of accrual is similar between no-DAC and with-DAC forms, though IGF-1 elevations are more sustained on the with-DAC form.

Weeks 8 to 12. First clinical reassessment in most protocols. IGF-1 is checked to confirm levels are in an appropriate physiologic range — particularly important on the with-DAC form, where sustained elevation can produce higher steady-state IGF-1 than the no-DAC pulsatile pattern. Body composition and subjective response are reassessed.

Months 3 to 6. Most courses run 3 to 6 months. Patients who have responded well may continue or cycle; non-responders may be candidates for protocol adjustment, a different form, or a different GHRH analog.

Cycling. Most clinicians use cycled protocols (e.g., 3 months on, 1 month off) rather than indefinite continuous use, reflecting the limited long-term safety data and a precautionary approach.

Monitoring on CJC-1295

Standard monitoring includes:

• IGF-1. Baseline and periodic measurement (typically every 8 to 12 weeks). Particularly important on the with-DAC form, where sustained elevation can drive higher steady-state IGF-1 than the no-DAC pulsatile pattern.
• Glucose and HbA1c. Baseline and periodic reassessment for glucose dysregulation.
• Lipid panel. Sometimes included as part of a broader cardiometabolic workup.
• Body composition. Waist circumference, weight, body fat percentage, or DEXA scan tracking depending on clinic protocol.
• Subjective response. Sleep, recovery, energy, and tolerability reviewed at follow-up visits.

Sourcing and Quality Considerations

Because CJC-1295 is not FDA-approved and is exclusively compounded, sourcing quality matters substantially. Tennessee patients should ask:

• Is the CJC-1295 sourced through a state-licensed 503A pharmacy with current state board of pharmacy registration?
• What batch testing does the pharmacy perform? Reputable pharmacies test each batch for purity (HPLC), sterility, and endotoxin content.
• Are certificates of analysis available on request?
• How is the peptide stored before reconstitution, and what shelf-life applies after reconstitution?

Internet “research peptide” channels are not legitimate sources for clinical use. These products are not regulated as drugs and have no quality assurance.

CJC-1295 Dosing Protocols

No-DAC dosing. Typical clinical protocols use 100 to 300 mcg by subcutaneous injection, 1 to 3 times daily. The most common pattern is once daily, pre-bed, combined with 200 to 300 mcg ipamorelin in a single combined-stack injection. Some protocols use additional doses post-workout or in the morning.

With-DAC dosing. Typical clinical protocols use 1 to 2 mg by subcutaneous injection once or twice weekly. The long half-life supports the low injection frequency.

Course duration. Typically 3 to 6 months followed by reassessment, with most clinicians using a cycled approach rather than indefinite continuous use. Cycling reflects a precautionary approach in the absence of robust long-term human data.

Your Tennessee provider should explain the specific protocol they recommend, the form (no-DAC vs with-DAC), and the rationale for the dose and frequency.

Side Effects and Safety

CJC-1295 is generally well-tolerated. Reported side effects include:

• Injection site reactions
• Flushing soon after injection
• Headache, typically transient
• Water retention (more prominent with the with-DAC form because of its sustained elevation profile)
• Transient hypoglycemia (uncommon)
• Sleep changes including vivid dreams (often reported as a positive)
• Numbness or tingling (uncommon)

Long-term safety data for chronic CJC-1295 use, particularly the with-DAC form with its sustained GH elevation, is limited. The cycled-use approach reflects this gap. Theoretical concerns about chronic GH/IGF-1 elevation include accelerating undiagnosed malignancy and producing glucose dysregulation — neither has been demonstrated as a clinically significant risk in available data but both are reasons for the standard contraindications.

Contraindications

CJC-1295 is contraindicated or generally avoided in patients with:

• Active malignancy
• Uncontrolled diabetes or significant glucose dysregulation
• Pregnancy and lactation
• Pediatric use
• Competitive athletic status under WADA jurisdiction (banned substance)
• Active proliferative diabetic retinopathy
• Known hypersensitivity to the peptide preparation

Patients with significant metabolic dysregulation, a history of cancer, or pituitary disorders should discuss risks carefully with a provider before initiation.

Legal and Regulatory Status

CJC-1295 is not FDA-approved for any indication. The peptide is available through some 503A compounding pharmacies under valid patient-specific prescriptions, which is the channel through which Tennessee clinics access it. WADA-banned status applies to competitive athletes.

The compounded-peptide regulatory environment continues to evolve, and patients should verify that any clinic they work with sources CJC-1295 from a state-licensed 503A pharmacy with appropriate quality controls — purity testing, sterility testing, and proper batch documentation. Internet “research peptide” channels are not legitimate sources for clinical use.

Finding a CJC-1295 Provider in Tennessee

CJC-1295 (almost always in combination with ipamorelin) is one of the most widely-available peptide protocols in Tennessee. Nashville and the Middle Tennessee corridor (Franklin, Brentwood, Murfreesboro, Hendersonville, Clarksville) have a substantial number of clinics offering CJC-1295/ipamorelin protocols, ranging from concierge medicine practices to functional medicine to dedicated peptide clinics. Knoxville, Chattanooga, Johnson City, Kingsport, and Memphis each have multiple providers with these protocols in regular practice.

Key questions to ask a Tennessee provider:

• Is CJC-1295 sourced through a state-licensed 503A compounding pharmacy with batch testing?
• Which form do you recommend — no-DAC or with-DAC — and what is the rationale for this patient?
• What is the recommended protocol, and how is it combined with ipamorelin (or other peptides)?
• What is the planned course duration and the cycling approach?
• What baseline and follow-up labs do you check (typically IGF-1, glucose/HbA1c, lipids)?
• What is the total monthly cost — medication, clinic visits, and labs included?

Clinics that articulate clear answers and that don’t treat the no-DAC vs with-DAC choice as interchangeable are generally the right ones to work with.

References

1. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.